Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 95


Role of the blood-brain barrier in metastatic disease of the central nervous system.

Berghoff AS, Preusser M.

Handb Clin Neurol. 2018;149:57-66. doi: 10.1016/B978-0-12-811161-1.00004-9.


Educational video: the role of PD-L1 in the local tumour microenvironment.

Preusser M, Berghoff AS, Thallinger C, Zielinski CC.

ESMO Open. 2017 Feb 1;1(6):e000137. doi: 10.1136/esmoopen-2016-000137. eCollection 2016.


CECOG educational illustrations: the blood-brain barrier and its relevance for targeted cancer therapies and immuno-oncology.

Preusser M, Berghoff AS, Thallinger C, Zielinski C.

ESMO Open. 2017 Jun 8;2(2):e000194. doi: 10.1136/esmoopen-2017-000194. eCollection 2017.


Correlation of immune phenotype with IDH mutation in diffuse glioma.

Berghoff AS, Kiesel B, Widhalm G, Wilhelm D, Rajky O, Kurscheid S, Kresl P, Wöhrer A, Marosi C, Hegi ME, Preusser M.

Neuro Oncol. 2017 Oct 19;19(11):1460-1468. doi: 10.1093/neuonc/nox054.


Next-Generation Sequencing-based genomic profiling of brain metastases of primary ovarian cancer identifies high number of BRCA-mutations.

Balendran S, Liebmann-Reindl S, Berghoff AS, Reischer T, Popitsch N, Geier CB, Kenner L, Birner P, Streubel B, Preusser M.

J Neurooncol. 2017 Jul;133(3):469-476. doi: 10.1007/s11060-017-2459-z. Epub 2017 May 11.


Decreased body mass index is associated with impaired survival in lung cancer patients with brain metastases: A retrospective analysis of 624 patients.

Masel EK, Berghoff AS, Füreder LM, Heicappell P, Schlieter F, Widhalm G, Gatterbauer B, Dieckmann U, Birner P, Bartsch R, Schur S, Watzke HH, Zielinski CC, Preusser M.

Eur J Cancer Care (Engl). 2017 Nov;26(6). doi: 10.1111/ecc.12707. Epub 2017 May 10.


Targeted Therapies for Melanoma Brain Metastases.

Berghoff AS, Preusser M.

Curr Treat Options Neurol. 2017 Apr;19(4):13. doi: 10.1007/s11940-017-0449-2. Review.


DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis.

Sahm F, Schrimpf D, Stichel D, Jones DTW, Hielscher T, Schefzyk S, Okonechnikov K, Koelsche C, Reuss DE, Capper D, Sturm D, Wirsching HG, Berghoff AS, Baumgarten P, Kratz A, Huang K, Wefers AK, Hovestadt V, Sill M, Ellis HP, Kurian KM, Okuducu AF, Jungk C, Drueschler K, Schick M, Bewerunge-Hudler M, Mawrin C, Seiz-Rosenhagen M, Ketter R, Simon M, Westphal M, Lamszus K, Becker A, Koch A, Schittenhelm J, Rushing EJ, Collins VP, Brehmer S, Chavez L, Platten M, Hänggi D, Unterberg A, Paulus W, Wick W, Pfister SM, Mittelbronn M, Preusser M, Herold-Mende C, Weller M, von Deimling A.

Lancet Oncol. 2017 May;18(5):682-694. doi: 10.1016/S1470-2045(17)30155-9. Epub 2017 Mar 15.


Validation of nuclear STAT6 immunostaining as a diagnostic marker of meningeal solitary fibrous tumor (SFT)/hemangiopericytoma.

Berghoff AS, Kresl P, Bienkowski M, Koelsche C, Rajky U, Hainfellner JA, Preusser M.

Clin Neuropathol. 2017 Mar/Apr;36 (2017)(2):56-59. doi: 10.5414/NP300993.


Combining standard clinical blood values for improving survival prediction in patients with newly diagnosed brain metastases-development and validation of the LabBM score.

Berghoff AS, Wolpert F, Holland-Letz T, Koller R, Widhalm G, Gatterbauer B, Dieckmann K, Birner P, Bartsch R, Zielinski CC, Weller M, Preusser M.

Neuro Oncol. 2017 Sep 1;19(9):1255-1262. doi: 10.1093/neuonc/now290.


Survival prediction using temporal muscle thickness measurements on cranial magnetic resonance images in patients with newly diagnosed brain metastases.

Furtner J, Berghoff AS, Albtoush OM, Woitek R, Asenbaum U, Prayer D, Widhalm G, Gatterbauer B, Dieckmann K, Birner P, Aretin B, Bartsch R, Zielinski CC, Schöpf V, Preusser M.

Eur Radiol. 2017 Aug;27(8):3167-3173. doi: 10.1007/s00330-016-4707-6. Epub 2017 Jan 3.


Cancer immune cycle: a video introduction to the interaction between cancer and the immune system.

Preusser M, Berghoff AS, Thallinger C, Zielinski CC.

ESMO Open. 2016 Apr 12;1(3):e000056. eCollection 2016.


Descriptive statistical analysis of a real life cohort of 2419 patients with brain metastases of solid cancers.

Berghoff AS, Schur S, Füreder LM, Gatterbauer B, Dieckmann K, Widhalm G, Hainfellner J, Zielinski CC, Birner P, Bartsch R, Preusser M.

ESMO Open. 2016 Mar 16;1(2):e000024. eCollection 2016.


Tumor infiltrating lymphocytes and PD-L1 expression in brain metastases of small cell lung cancer (SCLC).

Berghoff AS, Ricken G, Wilhelm D, Rajky O, Widhalm G, Dieckmann K, Birner P, Bartsch R, Preusser M.

J Neurooncol. 2016 Oct;130(1):19-29. Epub 2016 Jul 19.


In search of a target: PD-1 and PD-L1 profiling across glioma types.

Berghoff AS, Preusser M.

Neuro Oncol. 2016 Oct;18(10):1331-2. doi: 10.1093/neuonc/now162. Epub 2016 Aug 17. No abstract available.


Impact of Blood-Brain Barrier Integrity on Tumor Growth and Therapy Response in Brain Metastases.

Osswald M, Blaes J, Liao Y, Solecki G, Gömmel M, Berghoff AS, Salphati L, Wallin JJ, Phillips HS, Wick W, Winkler F.

Clin Cancer Res. 2016 Dec 15;22(24):6078-6087. Epub 2016 Aug 12.


Tumor-infiltrating lymphocyte subsets and tertiary lymphoid structures in pulmonary metastases from colorectal cancer.

Schweiger T, Berghoff AS, Glogner C, Glueck O, Rajky O, Traxler D, Birner P, Preusser M, Klepetko W, Hoetzenecker K.

Clin Exp Metastasis. 2016 Oct;33(7):727-39. doi: 10.1007/s10585-016-9813-y. Epub 2016 Jul 23.


Immune Checkpoint Inhibitors in Brain Metastases: From Biology to Treatment.

Berghoff AS, Venur VA, Preusser M, Ahluwalia MS.

Am Soc Clin Oncol Educ Book. 2016;35:e116-22. doi: 10.14694/EDBK_100005. Review.


Prognostic impact of breast cancer subtypes in elderly patients.

Bergen ES, Tichy C, Berghoff AS, Rudas M, Dubsky P, Bago-Horvath Z, Mader RM, Exner R, Gnant M, Zielinski CC, Steger GG, Preusser M, Bartsch R.

Breast Cancer Res Treat. 2016 May;157(1):91-9. doi: 10.1007/s10549-016-3787-y. Epub 2016 Apr 23.


A Cross-Sectional Study of Patients' Satisfaction With Totally Implanted Access Ports.

Minichsdorfer C, Füreder T, Mähr B, Berghoff AS, Heynar H, Dressler A, Gnant M, Zielinski C, Bartsch R.

Clin J Oncol Nurs. 2016 Apr;20(2):175-80. doi: 10.1188/16.CJON.175-180.


Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases.

Berghoff AS, Fuchs E, Ricken G, Mlecnik B, Bindea G, Spanberger T, Hackl M, Widhalm G, Dieckmann K, Prayer D, Bilocq A, Heinzl H, Zielinski C, Bartsch R, Birner P, Galon J, Preusser M.

Oncoimmunology. 2015 Jun 9;5(1):e1057388. eCollection 2016.


Genetic variants associated with colorectal brain metastases susceptibility and survival.

Stremitzer S, Berghoff AS, Volz NB, Zhang W, Yang D, Stintzing S, Ning Y, Sunakawa Y, Yamauchi S, Sebio A, Matsusaka S, Okazaki S, Hanna D, Parekh A, Mendez A, Berger MD, El-Khoueiry R, Birner P, Preusser M, Lenz HJ.

Pharmacogenomics J. 2017 Jan;17(1):29-35. doi: 10.1038/tpj.2015.86. Epub 2015 Dec 22.


Impact of oncogenic BRAF mutations and p16 expression on the growth rate of early melanomas and naevi in vivo.

Tschandl P, Berghoff AS, Preusser M, Pammer J, Pehamberger H, Kittler H.

Br J Dermatol. 2016 Feb;174(2):364-70. doi: 10.1111/bjd.14323. Epub 2016 Jan 9.


The PERS(2) ON score for systemic assessment of symptomatology in palliative care: a pilot study.

Masel EK, Berghoff AS, Schur S, Maehr B, Schrank B, Simanek R, Preusser M, Marosi C, Watzke HH.

Eur J Cancer Care (Engl). 2016 Jul;25(4):544-50. doi: 10.1111/ecc.12419. Epub 2015 Nov 12.


Brain tumour cells interconnect to a functional and resistant network.

Osswald M, Jung E, Sahm F, Solecki G, Venkataramani V, Blaes J, Weil S, Horstmann H, Wiestler B, Syed M, Huang L, Ratliff M, Karimian Jazi K, Kurz FT, Schmenger T, Lemke D, Gömmel M, Pauli M, Liao Y, Häring P, Pusch S, Herl V, Steinhäuser C, Krunic D, Jarahian M, Miletic H, Berghoff AS, Griesbeck O, Kalamakis G, Garaschuk O, Preusser M, Weiss S, Liu H, Heiland S, Platten M, Huber PE, Kuner T, von Deimling A, Wick W, Winkler F.

Nature. 2015 Dec 3;528(7580):93-8. doi: 10.1038/nature16071. Epub 2015 Nov 4.


Clinical Neuropathology mini-review 6-2015: PD-L1: emerging biomarker in glioblastoma?

Preusser M, Berghoff AS, Wick W, Weller M.

Clin Neuropathol. 2015 Nov-Dec;34(6):313-21. Review.


Psyche at the end of life: Psychiatric symptoms are prevalent in patients admitted to a palliative care unit.

Masel EK, Berghoff AS, Mladen A, Schur S, Maehr B, Kirchhoff M, Simanek R, Bauer M, Watzke HH, Amering M.

Palliat Support Care. 2016 Jun;14(3):250-8. doi: 10.1017/S1478951515000899. Epub 2015 Oct 8.


Kinetics of tumor size and peritumoral brain edema before, during, and after systemic therapy in recurrent WHO grade II or III meningioma.

Furtner J, Schöpf V, Seystahl K, Le Rhun E, Rudà R, Roelcke U, Koeppen S, Berghoff AS, Marosi C, Clement P, Faedi M, Watts C, Wick W, Soffietti R, Weller M, Preusser M.

Neuro Oncol. 2016 Mar;18(3):401-7. doi: 10.1093/neuonc/nov183. Epub 2015 Sep 9.


Activity of T-DM1 in Her2-positive breast cancer brain metastases.

Bartsch R, Berghoff AS, Vogl U, Rudas M, Bergen E, Dubsky P, Dieckmann K, Pinker K, Bago-Horvath Z, Galid A, Oehler L, Zielinski CC, Gnant M, Steger GG, Preusser M.

Clin Exp Metastasis. 2015 Oct;32(7):729-37. doi: 10.1007/s10585-015-9740-3. Epub 2015 Aug 25.


Clinical Neuropathology practice guide 5-2015: MGMT methylation pyrosequencing in glioblastoma: unresolved issues and open questions.

Bienkowski M, Berghoff AS, Marosi C, Wöhrer A, Heinzl H, Hainfellner JA, Preusser M.

Clin Neuropathol. 2015 Sep-Oct;34(5):250-7. Review.


Expression profiling of angiogenesis-related genes in brain metastases of lung cancer and melanoma.

Ilhan-Mutlu A, Siehs C, Berghoff AS, Ricken G, Widhalm G, Wagner L, Preusser M.

Tumour Biol. 2016 Jan;37(1):1173-82. doi: 10.1007/s13277-015-3790-7. Epub 2015 Aug 16.


The future of targeted therapies for brain metastases.

Berghoff AS, Preusser M.

Future Oncol. 2015;11(16):2315-27. doi: 10.2217/fon.15.127. Review.


Spectrum of gene mutations detected by next generation exome sequencing in brain metastases of lung adenocarcinoma.

Preusser M, Berghoff AS, Koller R, Zielinski CC, Hainfellner JA, Liebmann-Reindl S, Popitsch N, Geier CB, Streubel B, Birner P.

Eur J Cancer. 2015 Sep;51(13):1803-11. doi: 10.1016/j.ejca.2015.06.107. Epub 2015 Jul 8.


The inflammatory microenvironment in brain metastases: potential treatment target?

Berghoff AS, Preusser M.

Chin Clin Oncol. 2015 Jun;4(2):21. doi: 10.3978/j.issn.2304-3865.2015.06.03. Review.


Evaluation of tyrosine kinase receptors in brain metastases of clear cell renal cell carcinoma reveals cMet as a negative prognostic factor.

Schiefer AI, Mesteri I, Berghoff AS, Haitel A, Schmidinger M, Preusser M, Birner P.

Histopathology. 2015 Dec;67(6):799-805. doi: 10.1111/his.12709. Epub 2015 Jun 7.


Atypical sporadic CJD-MM phenotype with white matter kuru plaques associated with intranuclear inclusion body and argyrophilic grain disease.

Berghoff AS, Trummert A, Unterberger U, Ströbel T, Hortobágyi T, Kovacs GG.

Neuropathology. 2015 Aug;35(4):336-42. doi: 10.1111/neup.12192. Epub 2015 Mar 18.


Taxanes Plus Trastuzumab Compared To Oral Vinorelbine Plus Trastuzumab in HER2-Overexpressing Metastatic Breast Cancer.

Bergen E, Berghoff AS, Rudas M, Dubsky P, De Vries C, Sattlberger C, Mader RM, Zagouri F, Sparber C, Fitzal F, Gnant M, Rottenfusser A, Zielinski CC, Preusser M, Steger GG, Bartsch R.

Breast Care (Basel). 2014 Oct;9(5):344-8. doi: 10.1159/000368330. Erratum in: Breast Care (Basel). 2016 Feb;11(1):20.


Breast cancer brain metastases responding to lapatinib plus capecitabine as second-line primary systemic therapy.

Bergen ES, Berghoff AS, Rudas M, Preusser M, Bartsch R.

Anticancer Drugs. 2015 Jun;26(5):579-81. doi: 10.1097/CAD.0000000000000217.


Assessing MGMT methylation status and its current impact on treatment in glioblastoma.

Berghoff AS, Hainfellner JA, Marosi C, Preusser M.

CNS Oncol. 2015;4(1):47-52. doi: 10.2217/cns.14.50. Review.


Haematopoietic stem cell transplantation for treatment of primary CNS lymphoma: single-centre experience and literature review.

Bojic M, Berghoff AS, Troch M, Agis H, Sperr WR, Widhalm G, Wöhrer A, Kalhs P, Preusser M, Rabitsch W.

Eur J Haematol. 2015 Jul;95(1):75-82. doi: 10.1111/ejh.12482. Epub 2015 Mar 23. Review.


Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma.

Berghoff AS, Kiesel B, Widhalm G, Rajky O, Ricken G, Wöhrer A, Dieckmann K, Filipits M, Brandstetter A, Weller M, Kurscheid S, Hegi ME, Zielinski CC, Marosi C, Hainfellner JA, Preusser M, Wick W.

Neuro Oncol. 2015 Aug;17(8):1064-75. doi: 10.1093/neuonc/nou307. Epub 2014 Oct 29.


Tumour-infiltrating lymphocytes and expression of programmed death ligand 1 (PD-L1) in melanoma brain metastases.

Berghoff AS, Ricken G, Widhalm G, Rajky O, Dieckmann K, Birner P, Bartsch R, Höller C, Preusser M.

Histopathology. 2015 Jan;66(2):289-99. doi: 10.1111/his.12537. Epub 2014 Nov 10.


Predictive molecular markers in metastases to the central nervous system: recent advances and future avenues.

Berghoff AS, Bartsch R, Wöhrer A, Streubel B, Birner P, Kros JM, Brastianos PK, von Deimling A, Preusser M.

Acta Neuropathol. 2014 Dec;128(6):879-91. doi: 10.1007/s00401-014-1350-7. Epub 2014 Oct 7. Review.


BRAF alterations in brain tumours: molecular pathology and therapeutic opportunities.

Berghoff AS, Preusser M.

Curr Opin Neurol. 2014 Dec;27(6):689-96. doi: 10.1097/WCO.0000000000000146. Review.


Differential role of angiogenesis and tumour cell proliferation in brain metastases according to primary tumour type: analysis of 639 cases.

Berghoff AS, Ilhan-Mutlu A, Dinhof C, Magerle M, Hackl M, Widhalm G, Hainfellner JA, Dieckmann K, Pichler J, Hutterer M, Melchardt T, Bartsch R, Zielinski CC, Birner P, Preusser M.

Neuropathol Appl Neurobiol. 2015 Feb;41(2):e41-55. doi: 10.1111/nan.12185.


αvβ3, αvβ5 and αvβ6 integrins in brain metastases of lung cancer.

Berghoff AS, Kovanda AK, Melchardt T, Bartsch R, Hainfellner JA, Sipos B, Schittenhelm J, Zielinski CC, Widhalm G, Dieckmann K, Weller M, Goodman SL, Birner P, Preusser M.

Clin Exp Metastasis. 2014 Oct;31(7):841-51. doi: 10.1007/s10585-014-9675-0. Epub 2014 Aug 24.


Detection of disease-associated α-synuclein in the cerebrospinal fluid: a feasibility study.

Unterberger U, Lachmann I, Voigtländer T, Pirker W, Berghoff AS, Flach K, Wagner U, Geneste A, Perret-Liaudet A, Kovacs GG.

Clin Neuropathol. 2014 Sep-Oct;33(5):329-34.


MAP kinase activity supported by BRAF (V600E) mutation rather than gene amplification is associated with ETV1 expression in melanoma brain metastases.

Birner P, Berghoff AS, Dinhof C, Pirker C, Capper D, Schoppmann SF, Petzelbauer P, von Deimling A, Berger W, Preusser M.

Arch Dermatol Res. 2014 Dec;306(10):873-84. doi: 10.1007/s00403-014-1490-6. Epub 2014 Jul 30.


A patient diagnosed with BRAF-mutated non-small cell lung cancer and hairy cell leukemia: at last, which entity is really carrying the BRAF mutation?

Schlick K, Troch M, Placher-Sorko G, Faber V, Neureiter D, Berghoff AS, Preusser M, Greil R, Hopfinger G.

Ann Hematol. 2015 Feb;94(2):345-6. doi: 10.1007/s00277-014-2162-5. Epub 2014 Jul 24. No abstract available.


Amplification and overexpression of CMET is a common event in brain metastases of non-small cell lung cancer.

Preusser M, Streubel B, Berghoff AS, Hainfellner JA, von Deimling A, Widhalm G, Dieckmann K, Wöhrer A, Hackl M, Zielinski C, Birner P.

Histopathology. 2014 Nov;65(5):684-92. doi: 10.1111/his.12475. Epub 2014 Aug 5.


Supplemental Content

Loading ...
Support Center